Sparrow Pharmaceuticals is a clinical stage, private biopharmaceutical company developing targeted therapeutics for serious disorders of steroid excess.

Indalo Therapeutics is a preclinical-stage biotechnology company backed by Atlas and F-Prime dedicated to improving the lives of patients suffering from debilitating fibrotic diseases.

OrbiMed is a leading healthcare focused investment firm with over $14 billion under management across public and private company investments worldwide.

Symbiomix is a late-stage biopharmaceutical company with a focus on women's health backed by OrbiMed, F-Prime, and HBM Partners. Symbiomix developed Solosec™ from pre-clinical candidate through NDA approval in less than five years before being sold to Lupin Inc. in 2017.

Professional services to the biotechnology and pharmaceutical industries in the areas of business development, fund raising, commercial analysis, valuation, and product development strategy. Clients include: Invida Pharmaceuticals, a specialty pharmaceutical company with operations across Asia Pacific; SMC Biotechnology, a private company with innovative regenerative medicine technology; Alliqua, a biomedical company focused on the development, manufacturing and marketing of proprietary products in wound healing; and PopTest, a start-up with a non-invasive and user-friendly diagnostic platform.

Leadership Team member for private biotech with a CCR5/CCR2 antagonist in development for HIV. Led business development efforts, participated in Series B financing.

Responsible for partnering strategy and execution for venture financed oncology spin-out from Bayer Healthcare with four oral kinase inhibitor programs.

Led Licensing Leadership Teams for Infectious Diseases, Oncology and Ophthalmology. Created sourcing strategies and plans, identified and evaluated opportunities, formed and led cross-functional analysis teams, presented to management and interfaced with potential partners.

Led commercial assessment teams and early marketing strategy for Infectious Diseases and Oncology. Designed clinical development and regulatory strategies for pipeline products. Recommended target launch positioning and investment plans to create differentiation and maximize value.